In a phase 1 trial of patients with melanoma patients and who received melanoma antigen recognized by T-cell 1 (MART1) peptide vaccinations with or without IMP321, those treated with IMP321 presented decreased expression of PD-1, LAG-3, TIM-3, CD244, and CD160 [11]. This evidence concerns the gene HAVCR2 and melanoma.